 |
|
MAFLD: How is it different from NAFLD?
Cameron Gofton, Yadhavan Upendran, Ming-Hua Zheng, Jacob George
Clin Mol Hepatol. 2023;29(Suppl):S17-S31. Published online 2022 Nov 29 DOI: https://doi.org/10.3350/cmh.2022.0367
|
|
Citations to this article as recorded by
 Obesity in Adults: Position Statement of Polish Association for the Study on Obesity, Polish Association of Endocrinology, Polish Association of Cardiodiabetology, Polish Psychiatric Association, Section of Metabolic and Bariatric Surgery of the Associati
Magdalena Olszanecka-Glinianowicz, Artur Mazur, Jerzy Chudek, Beata Kos-Kudła, Leszek Markuszewski, Dominika Dudek, Piotr Major, Piotr Małczak, Wiesław Tarnowski, Paweł Jaworski, Elżbieta Tomiak
Nutrients.2023; 15(7): 1641. CrossRef Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology
Eileen Laurel Yoon, Dae Won Jun
Clinical and Molecular Hepatology.2023; 29(2): 371. CrossRef Type 2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, and Metabolic Repercussions: The Vicious Cycle and Its Interplay with Inflammation
Rafał Frankowski, Mateusz Kobierecki, Andrzej Wittczak, Monika Różycka-Kosmalska, Tadeusz Pietras, Kasper Sipowicz, Marcin Kosmalski
International Journal of Molecular Sciences.2023; 24(11): 9677. CrossRef MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study
Eugene Han, Ho Soo Chun, Yong‐ho Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Byung‐Wan Lee, Eun Seok Kang, Bong‐Soo Cha, Sang Hoon Ahn, Seung Up Kim
Journal of Gastroenterology and Hepatology.2023; 38(9): 1598. CrossRef The impact of concomitant metabolic dysfunction-associated fatty liver disease on adverse outcomes in patients with hepatitis B cirrhosis: a propensity score matching study
Xinyu Wang, Shuhang Wei, Yingnan Wei, Xueqi Wang, Feng Xiao, Yuemin Feng, Qiang Zhu
European Journal of Gastroenterology & Hepatology.2023; 35(8): 889. CrossRef Metabolic dysfunction: The silenced connection with fatty liver disease
Mariana M. Ramírez-Mejía, Xingshun Qi, Ludovico Abenavoli, Manuel Romero-Gómez, Mohammed Eslam, Nahum Méndez-Sánchez
Annals of Hepatology.2023; 28(6): 101138. CrossRef MAFLD: an optimal framework for understanding liver cancer phenotypes
Harry Crane, Cameron Gofton, Ankur Sharma, Jacob George
Journal of Gastroenterology.2023; 58(10): 947. CrossRef Liver Fibrosis Scores and Coronary Artery Disease: Novel Findings in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease
Chuan Lu, Yan Chen, Yue Zhang, Xin Zhao
Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 2627. CrossRef Current insights into the interplay between gut microbiota-derived metabolites and metabolic-associated fatty liver disease
Rachmad Anres Dongoran, Fang-Cen Tu, Chin-Hung Liu
Tzu Chi Medical Journal.2023; 35(4): 290. CrossRef New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut–Liver–Heart Crosstalk
Keungmo Yang, Myeongjun Song
Nutrients.2023; 15(18): 3970. CrossRef Meeting at the Crossroad between Obesity and Hepatic Carcinogenesis: Unique Pathophysiological Pathways Raise Expectations for Innovative Therapeutic Approaches
Konstantinos Arvanitakis, Stavros P. Papadakos, Vasileios Lekakis, Theocharis Koufakis, Ioannis G. Lempesis, Eleni Papantoniou, Georgios Kalopitas, Vasiliki E. Georgakopoulou, Ioanna E. Stergiou, Stamatios Theocharis, Georgios Germanidis
International Journal of Molecular Sciences.2023; 24(19): 14704. CrossRef Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease
Aleksandra Bołdys, Łukasz Bułdak, Mateusz Maligłówka, Stanisław Surma, Bogusław Okopień
Medicina.2023; 59(10): 1789. CrossRef Association between different modalities of insulin administration and metabolic dysfunction-associated fatty liver disease in adults with type 1 diabetes mellitus
Alessandro Csermely, Alessandro Mantovani, Mario Luca Morieri, Luisa Palmisano, Maria Masulli, Efisio Cossu, Marco Giorgio Baroni, Katia Bonomo, Flavia Agata Cimini, Gisella Cavallo, Raffaella Buzzetti, Carmen Mignogna, Frida Leonetti, Simonetta Bacci, Ro
Diabetes & Metabolism.2023; 49(6): 101477. CrossRef Pre-MASLD: Should it be defined separately?
Hang-Kai Huang, You-Ming Li, Cheng-Fu Xu
Hepatobiliary & Pancreatic Diseases International.2023;[Epub] CrossRef Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
Gi-Ae Kim, Joon Ho Moon, Won Kim
Clinical and Molecular Hepatology.2023; 29(4): 831. CrossRef From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials
Ming-Lun Yeh, Ming-Lung Yu
Clinical and Molecular Hepatology.2023; 29(4): 969. CrossRef The heterogeneity of metabolic syndrome presentation and challenges this causes in its pharmacological management: a narrative review focusing on principal risk modifiers
Amedeo Lonardo
Expert Review of Clinical Pharmacology.2023; 16(10): 891. CrossRef Vascular calcification: from the perspective of crosstalk
Shiqi Yang, Zhaolin Zeng, Qing Yuan, Qian Chen, Zuo Wang, Hui Xie, Jianghua Liu
Molecular Biomedicine.2023;[Epub] CrossRef What Is in a Name: from NAFLD to MAFLD and MASLD—Unraveling the Complexities and Implications
Mariana M. Ramírez-Mejía, Nahum Méndez-Sánchez
Current Hepatology Reports.2023;[Epub] CrossRef Crosstalk between Lipids and Non-Alcoholic Fatty Liver Disease
Divyavani Gowda, Chandra Shekhar, Siddabasave Gowda B. Gowda, Yifan Chen, Shu-Ping Hui
Livers.2023; 3(4): 687. CrossRef Object detection: A novel AI technology for the diagnosis of hepatocyte ballooning
Tian‐Lei Zheng, Jun‐Cheng Sha, Qian Deng, Shi Geng, Shu‐Yuan Xiao, Wen‐Jun Yang, Christopher D. Byrne, Giovanni Targher, Yang‐Yang Li, Xiang‐Xue Wang, Di Wu, Ming‐Hua Zheng
Liver International.2023;[Epub] CrossRef
|